Changchun Zhuoyi Biological
Changchun Zhuoyi Biological Co., Ltd., founded in 2005, is a high-tech enterprise integrating research, production, and sales of biological vaccines. It independently developed and produces a freeze-dried human rabies vaccine (Vero cells), which passed national GMP certification in 2016, becoming the first in the province to obtain registration and GMP certificates through combined inspection. The vaccine was launched in 2017, marking efficient transition from research to production. The company focuses on disease prevention with advanced biotechnology to ensure stable vaccine quality. It operates a 41,600 sqm facility with annual output value exceeding 100 million RMB and has an advanced vaccine R&D center capable of molecular to individual-level research. In 2020, it began building a new WHO PQ-compliant production and R&D base with smart workshops to expand production and international competitiveness. The company strictly follows GMP standards and upgraded to ISO9001 and ISO14000 certifications in 2021, implementing AI digital management systems to enhance quality and operational efficiency. It holds 47 patents including 11 invention patents and collaborates with top research institutes for vaccine innovation. Recognized as a "Science and Technology Little Giant" and high-tech enterprise, it emphasizes intellectual property management and talent development, with over 50% employees holding bachelor's degrees or higher. Zhuoyi actively cooperates with WHO to provide safe, effective vaccines globally, aiming to contribute to public health and national rejuvenation.
Changchun Zhuoyi Biological
Changchun Zhuoyi Biological Co., Ltd., founded in 2005, is a high-tech enterprise integrating research, production, and sales of biological vaccines. It independently developed and produces a freeze-dried human rabies vaccine (Vero cells), which passed national GMP certification in 2016, becoming the first in the province to obtain registration and GMP certificates through combined inspection. The vaccine was launched in 2017, marking efficient transition from research to production. The company focuses on disease prevention with advanced biotechnology to ensure stable vaccine quality. It operates a 41,600 sqm facility with annual output value exceeding 100 million RMB and has an advanced vaccine R&D center capable of molecular to individual-level research. In 2020, it began building a new WHO PQ-compliant production and R&D base with smart workshops to expand production and international competitiveness. The company strictly follows GMP standards and upgraded to ISO9001 and ISO14000 certifications in 2021, implementing AI digital management systems to enhance quality and operational efficiency. It holds 47 patents including 11 invention patents and collaborates with top research institutes for vaccine innovation. Recognized as a "Science and Technology Little Giant" and high-tech enterprise, it emphasizes intellectual property management and talent development, with over 50% employees holding bachelor's degrees or higher. Zhuoyi actively cooperates with WHO to provide safe, effective vaccines globally, aiming to contribute to public health and national rejuvenation.